References
- Barnosky A, Shah L, Meah F, et al. A primer on concentrated insulins: what an internist should know. Postgrad Med. 2016;128:381–390.
- de la Peña A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34:2496–2501.
- Humulin® R U-500 [package insert]. Indianapolis IN: Eli Lilly and Company; 2016.
- Segal AR, Brunner JE, Burch FT, et al. Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health-Syst Pharm. 2010;67:1526–1535.
- Hood RC, Arakaki RF, Wysham C, et al. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract. 2015;21:782–793.
- Wysham C, Hood RC, Warren ML, et al. Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes. Endocr Pract. doi:10.4158/EP15959.OR. Epub 2016 20 Jan.